Want to see CING full AI Analyst Report?
CING Stock Chart & Stats
$4.64
-$0.13(-2.91%)
At close: 4:00 PM EDT
$4.64
-$0.13(-2.91%)
Day’s Range― - ―
52-Week Range$3.16 - $11.89
Previous CloseN/A
Volume78.30K
Average Volume (3M)190.99K
Market Cap
$64.52M
Enterprise Value$10.24M
Total Cash (Recent Filing)$25.89M
Total Debt (Recent Filing)$7.43M
Price to Earnings (P/E)―
Beta5.01
Next Earnings
Aug 18, 2026EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.02
Shares Outstanding13,469,036
10 Day Avg. Volume270,731
30 Day Avg. Volume190,985
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.40
Price to Sales (P/S)0.00
P/FCF Ratio-1.35
Enterprise Value/Market Cap0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.43
Forecast
1Y Price Target
$22.50Price Target Upside384.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.42
Revenue Forecast (FY)$3.63M
Bulls Say, Bears Say
Bulls Say
Patent ProtectionA fully owned U.S. patent extending exclusivity to 2042 secures long-term market protection for the lead ADHD formulation. This durable IP reduces generic risk, strengthens licensing and partner negotiation leverage, and underpins the commercial value of the PTR platform across markets.
Platform DifferentiationThe PTR platform is a structural competitive advantage: it targets symptom-timed dosing and supports multi-product application across ADHD and anxiety. Platform-based formulations can lower development marginal costs, improve patient adherence, and create a repeatable route to a differentiated pipeline.
Near-term Cash RunwayReported near-$30M cash provides runway to complete CMC tasks, resubmit the NDA and fund pre-commercial work into 2027. This reduces immediate refinancing pressure, allowing management to address regulatory requirements without urgent dilution and maintain program momentum in the near term.
Bears Say
No Revenue / Sustained LossesMulti-year zero revenue with recurring net losses (roughly $15M–$24M annually) indicates reliance on external funding and long lead times to commercialization. Persistent losses limit internal funding capacity, increase dilution risk, and reduce resilience to regulatory or market setbacks.
Leverage And Balance Sheet RiskElevated debt relative to equity and a history of negative equity signal constrained financial flexibility. High leverage increases cost of capital, heightens refinancing risk if approvals slip, and can force dilutive financings or unfavorable terms that impair long-term strategic options.
Regulatory SetbackThe FDA CRL centered on CMC matters delays approval and commercialization timelines, likely increasing development and manufacturing costs. Such manufacturing-focused deficiencies can require process upgrades, additional validation, and extend time to market, materially affecting revenue onset and partner confidence.
Cingulate Inc News
CING FAQ
What was Cingulate Inc’s price range in the past 12 months?
Cingulate Inc lowest stock price was $3.16 and its highest was $11.89 in the past 12 months.
What is Cingulate Inc’s market cap?
Cingulate Inc’s market cap is $64.52M.
When is Cingulate Inc’s upcoming earnings report date?
Cingulate Inc’s upcoming earnings report date is Aug 18, 2026 which is in 16 days.
How were Cingulate Inc’s earnings last quarter?
Cingulate Inc released its earnings results on May 14, 2026. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.52 by -$0.43.
Is Cingulate Inc overvalued?
According to Wall Street analysts Cingulate Inc’s price is currently Undervalued.
Does Cingulate Inc pay dividends?
Cingulate Inc does not currently pay dividends.
What is Cingulate Inc’s EPS estimate?
Cingulate Inc’s EPS estimate is -0.63.
How many shares outstanding does Cingulate Inc have?
Cingulate Inc has 13,469,036 shares outstanding.
What happened to Cingulate Inc’s price movement after its last earnings report?
Cingulate Inc reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.52. Following the earnings report the stock price went down -10.772%.
Which hedge fund is a major shareholder of Cingulate Inc?
Currently, no hedge funds are holding shares in CING
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cingulate Inc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.50 (384.91% Upside)
$22.50 (384.91% Upside)
Hedge Fund Trend
Decreased
By 97.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $490.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
147.50%
Trailing 12-Months
Company Description
Cingulate Inc
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
CING Stock 12 Month Forecast
Average Price Target
$22.50
▲(384.91% Upside)
Technical Analysis
Bio Green Med Solution
―
NanoViricides
―
Enlivex
―
FibroBiologics, Inc.
―
Boundless Bio Inc.
―
Ownership Overview
1.93% Insiders
2.80% Mutual Funds
0.22% Other Institutional Investors
90.72% Public Companies and
Individual Investors